MAD7 is a novel nuclease that was released by Inscripta in 2017. This nuclease only requires a crRNA for gene editing and allows for specific targeting of AT rich regions of the genome. MAD7 cleaves DNA with a staggered cut as compared to S. pyogenes which has blunt cutting.
MAD7 is a novel nuclease that was released by Inscripta in 2017. This nuclease only requires a crRNA for gene editing and allows for specific targeting of AT rich regions of the genome. MAD7 cleaves DNA with a staggered cut as compared to S. pyogenes which has blunt cutting.
This mRNA features:
- A Cap 1 structure with high capping efficiency
- Codon optimized using GenScript X5 algorithm to enhance expression efficiency
- 100% substitution with N1-methyl-pseudouridine (m1Ψ) for improved protein expression and reduced innate immune response
- GenScript’s patented UTR to enhance translation
- A 100A poly(A) tail to mimic natural mature mRNA
Transfect 2μg of MAD7 mRNA and 0.4μg of guide RNA into 5×104 HEK293T cells through Lipofectamine™ MessengerMAX™ (or equivalent). 48-72 hours after transfection, extract genomic DNA, and amplify the target region by PCR. Analyze the PCR products through NGS sequencing.
